Background and Objectives: As the global aging population grows, the incidence of thyroidectomy in elderly patients is increasing. This study aimed to evaluate the surgical outcomes of thyroidectomy in patients aged 80 years and older. Materials and Methods: All patients aged 80 years and older who underwent thyroidectomies at our hospital between January 2015 and December 2022 were reviewed in this retrospective cohort study. Collected data consisted of patients’ clinical characteristics, functional status, compression symptoms, preoperative assessments, perioperative outcomes, postoperative complications (such as bleeding events, recurrent laryngeal nerve injury, hypocalcemia), pathological findings, readmission, and follow-up outcomes. Results: Seventeen patients were included in this study, with female predominance (82.4%). The mean age was 85.6 ± 4.8 years. Fourteen patients (82.4%) exhibited compression-related symptoms as surgical indications. Based on pathological reports, patients were categorized into benign (12/17, 70.6%) and malignancy (5/17, 29.4%) groups. The benign group had a shorter operation time compared with the malignancy group (164.3 ± 32.0 min vs. 231.0 ± 79.1 min, p = 0.048). No major postoperative complications developed. The median postoperative follow-up duration was 28 months (range: 2–91 months). Thirteen patients (76.5%) were alive at the end of the study period. Conclusions: Despite potential age-related risks, thyroidectomy is feasible for carefully selected patients aged 80 years and older. It provides benefits not only in terms of oncological curative treatment but also in improving the quality of life, such as compressive symptoms and wound condition.

Background: Data on the immunogenicity of mRNA vaccines in solid transplant recipients are emerging; however, data on liver transplant recipients of Taiwanese ethnicity remain limited. Methods: We recruited 33 Taiwanese liver transplant recipients who received two doses of the Moderna mRNA-1273 vaccine and obtained blood samples for the semiquantitative determination of antibodies to the severe acute respiratory syndrome coronavirus 2 S protein RBD (receptor-binding domain) 2 weeks after each vaccination. The participants were also required to note any adverse events 1 week after the booster vaccination. Results: Antibody response after the priming and booster doses of the mRNA-1273 vaccine was 50% and 100%, respectively. The participants were further stratified into optimal (n = 27, >250 U/mL) and inadequate (n = 6, <250 U/mL) response groups according to the upper limit of the numeric antibody titer. A shorter time after transplantation and lower estimated glomerular filtration rate were significantly associated with an inadequate titer. The postvaccination humoral response seemed unaffected by use of antimetabolites. No severe adverse events were reported. Conclusions: The postvaccination immunogenicity of Taiwanese liver transplant recipients was satisfactory, whereas the reactogenicity to the novel vaccine was minimal.